These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16892355)

  • 1. Aroyl-pyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition.
    Mai A; Massa S; Valente S; Simeoni S; Ragno R; Bottoni P; Scatena R; Brosch G
    ChemMedChem; 2006 Feb; 1(2):225-37. PubMed ID: 16892355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
    Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
    Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
    Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
    J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
    Ragno R; Mai A; Massa S; Cerbara I; Valente S; Bottoni P; Scatena R; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2004 Mar; 47(6):1351-9. PubMed ID: 14998325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
    Mai A; Massa S; Pezzi R; Simeoni S; Rotili D; Nebbioso A; Scognamiglio A; Altucci L; Loidl P; Brosch G
    J Med Chem; 2005 May; 48(9):3344-53. PubMed ID: 15857140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
    Mai A; Massa S; Pezzi R; Rotili D; Loidl P; Brosch G
    J Med Chem; 2003 Nov; 46(23):4826-9. PubMed ID: 14584932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity.
    Mai A; Valente S; Rotili D; Massa S; Botta G; Brosch G; Miceli M; Nebbioso A; Altucci L
    Int J Biochem Cell Biol; 2007; 39(7-8):1510-22. PubMed ID: 17482499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
    Andrianov V; Gailite V; Lola D; Loza E; Semenikhina V; Kalvinsh I; Finn P; Petersen KD; Ritchie JW; Khan N; Tumber A; Collins LS; Vadlamudi SM; Björkling F; Sehested M
    Eur J Med Chem; 2009 Mar; 44(3):1067-85. PubMed ID: 18672316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.
    Valente S; Tardugno M; Conte M; Cirilli R; Perrone A; Ragno R; Simeoni S; Tramontano A; Massa S; Nebbioso A; Miceli M; Franci G; Brosch G; Altucci L; Mai A
    ChemMedChem; 2011 Apr; 6(4):698-712. PubMed ID: 21374822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors.
    Mai A; Massa S; Pezzi R; Valente S; Loidl P; Brosch G
    Med Chem; 2005 May; 1(3):245-54. PubMed ID: 16787320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase.
    Marson CM; Mahadevan T; Dines J; Sengmany S; Morrell JM; Alao JP; Joel SP; Vigushin DM; Charles Coombes R
    Bioorg Med Chem Lett; 2007 Jan; 17(1):136-41. PubMed ID: 17046252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
    Ragno R; Simeoni S; Rotili D; Caroli A; Botta G; Brosch G; Massa S; Mai A
    Eur J Med Chem; 2008 Mar; 43(3):621-32. PubMed ID: 17698257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
    Mai A; Massa S; Ragno R; Esposito M; Sbardella G; Nocca G; Scatena R; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2002 Apr; 45(9):1778-84. PubMed ID: 11960489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
    Moradei O; Leit S; Zhou N; Fréchette S; Paquin I; Raeppel S; Gaudette F; Bouchain G; Woo SH; Vaisburg A; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Li Z; Rahil J; MacLeod AR; Besterman JM; Delorme D
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4048-52. PubMed ID: 16713259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
    Witter DJ; Harrington P; Wilson KJ; Chenard M; Fleming JC; Haines B; Kral AM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Jan; 18(2):726-31. PubMed ID: 18060775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
    Zubia A; Ropero S; Otaegui D; Ballestar E; Fraga MF; Boix-Chornet M; Berdasco M; Martinez A; Coll-Mulet L; Gil J; Cossío FP; Esteller M
    Oncogene; 2009 Mar; 28(11):1477-84. PubMed ID: 19169274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.